Sunny Pharmtech

Sunny Pharmtech EBIT Margin

The EBIT Margin (Operating Margin) of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -38.99 %. In the previous year, EBIT Margin (Operating Margin) was -16.81 % — a change of 131.92% (lower).

EBIT Margin

-38.99 %

YoY

131.92%

Last updated:

EBIT Margin (Operating Margin) of Sunny Pharmtech is 2024 -38.99 % . EBIT Margin (Operating Margin) of Sunny Pharmtech was 2023 -16.81 % . It decreases by 131.92% lower compared to the previous year.

Sunny Pharmtech's operating (EBIT) margin stands at -39.0%, down from -17.7% several years earlier.

The Sunny Pharmtech EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-209.39 TWD
Jan 1, 2019
-91.28 TWD
Jan 1, 2020
-17.70 TWD
Jan 1, 2021
-73.03 TWD
Jan 1, 2022
-52.18 TWD
Jan 1, 2023
-16.81 TWD
Jan 1, 2024
-38.99 TWD
The Sunny Pharmtech EBIT Margin history
YEAREBIT MarginYoY
-38.99 %+131.92%
-16.81 %-67.78%
-52.18 %-28.56%
-73.03 %+312.54%
-17.70 %-80.61%
-91.28 %-56.40%
-209.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

EBIT Margin (Operating Margin) of Sunny Pharmtech is -38.99 % in 2024.

EBIT Margin (Operating Margin) of Sunny Pharmtech changed from -16.81 % to -38.99 %, representing a 131.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech